+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects of adenosine triphosphate on pulmonary circulation in chronic obstructive pulmonary disease. ATP: a pulmonary vasoregulator?



Effects of adenosine triphosphate on pulmonary circulation in chronic obstructive pulmonary disease. ATP: a pulmonary vasoregulator?



American Review of Respiratory Disease 134(6): 1140-1144



Extracellular adenosine triphosphate (ATP) has potent systemic vasodilator and endothelial-dependent relaxant effects on precontracted vessels. Pulmonary uptake and metabolism of ATP have been described, but experimental effects on pulmonary vessels remain controversial in animals. The effects of an intravenously administered infusion of ATP on pulmonary hemodynamic and gasometric data were assessed in 18 patients with stable chronic obstructive pulmonary disease (COPD). Low doses of ATP (successive rates, 1 and 2 mumol/kg body weight, each for 20 min) were infused in pulmonary hypertensive (H; n = 6) and nonhypertensive (N; n = 6) patients. They were compared with a control group (C; n = 6) that received only solvent, using ANOVA. During ATP infusion, a significant pulmonary vasodilation was demonstrated as simultaneous decreases reached, respectively, -14.2% (Group H; p less than 0.005) and -13.8% (Group N; p less than 0.001) for mean pulmonary artery pressure (Ppa), and -31.7% (H; p less than 0.05) and -20.7% (N; p less than 0.01) for pulmonary vascular resistances (PVR), associated with some worsening of hypoxemia: -6.9% (H; p less than 0.01) and -11.8% (n; p less than 0.005). After ATP withdrawal, significant rebound of these data (above baseline values) reached +10.9% (H; p less than 0.05) and +4.4% (N; p less than 0.05) for Ppa and +24.9% (H; p less than 0.05) and +10.2% (N; p = NS) for PVR. At the low infusion rate used, ATP appeared to be a well-tolerated, short-acting, selective pulmonary vasolidating compound in patients with COPD, but therapeutic use remains premature.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039957332

Download citation: RISBibTeXText

PMID: 3789516


Related references

Comparison of pulmonary and systemic effects of adenosine triphosphate in chronic obstructive pulmonary disease--ATP: a pulmonary controlled vasoregulator?. European Respiratory Journal 3(4): 450-455, 1990

Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. Journal of the American Medical Directors Association 18(12): 1063-1068, 2018

Behavior of the pulmonary circulation in chronic obstructive pulmonary disease. Pathogenesis of pulmonary arterial hypertension at an attitude of 2,240 meters. American Review of Respiratory Disease 126(3): 509-514, 1982

Disappearance of molsidomine effects on pulmonary circulation of patients with chronic obstructive pulmonary disease after a three week treatment. Pathologie-Biologie 39(1): 29-33, 1991

Hemodynamic effects of ibopamine on the pulmonary circulation and right ventricular performance in patients with chronic obstructive pulmonary disease. Cardiology 80(5-6): 349-355, 1992

Hemodynamic Effects of Ibopamine on the Pulmonary Circulation and Right Ventricular Performance in Patients with Chronic Obstructive Pulmonary Disease. Cardiology 80(5-6): 349-355, 1992

Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 181(9): 928-934, 2010

Correlation of chronic obstructive pulmonary disease assessment test and clinical chronic obstructive pulmonary disease questionnaire score with BODE index in patients of stable chronic obstructive pulmonary disease. Lung India 35(6): 494-498, 2018

Contribution of multiple inert gas elimination technique to pulmonary medicine. 2. Chronic pulmonary diseases: chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Thorax 49(9): 924-932, 1994

Effects of pulmonary vascular abnormalities on hypoxic pulmonary vasoconstriction in mild chronic obstructive pulmonary disease. American Review of Respiratory Disease 143(4 PART 2): A178, 1991

Repetitive hemodilution in chronic obstructive pulmonary disease and pulmonary hypertension: effects on pulmonary hemodynamics, gas exchange, and exercise capacity. Respiration; International Review of Thoracic Diseases 66(3): 225-232, 1999

Repetitive Hemodilution in Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: Effects on Pulmonary Hemodynamics, Gas Exchange, and Exercise Capacity. Respiration 66(3): 225-232, 1999

Prevalence of pulmonary artery hypertension in patients of chronic obstructive pulmonary disease and its correlation with stages of chronic obstructive pulmonary disease, exercising capacity, and quality of life. Journal of Family Medicine and Primary Care 7(1): 53-57, 2018

Distinct differences in gene expression patterns in pulmonary arteries of patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis with pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 190(1): 98-111, 2014

Adenosine A2B receptor and hyaluronan modulate pulmonary hypertension associated with chronic obstructive pulmonary disease. American Journal of Respiratory Cell and Molecular Biology 49(6): 1038-1047, 2014